

PRESS RELEASE



ExonHit Therapeutics announces the appointment of its new Chief Financial Officer

Paris, France, November 5, 2009 - ExonHit Therapeutics (Alternext: ALEHT) today announced the appointment of Hervé Duchesne de Lamotte as its Chief Financial Officer. Hervé Duchesne de Lamotte has over 25 years of international financial experience, including 10 years within the biotechnology industry.

"We are very pleased to welcome Hervé Duchesne de Lamotte to the Company. He will provide ExonHit with the benefit of his strong financial experience in the healthcare field and his international skills in strategy and consulting - all of which are significant assets for the pursuit of our corporate objectives", stated Loïc Maurel M.D., President of ExonHit Therapeutics' Management Board.

"We are delighted to have attracted a finance professional of Hervé's quality. ExonHit will notably benefit from his biotech management experience and his paramount concern for shareholder value creation. His track record in implementing and monitoring business strategies - including external growth opportunities - is a strong point for ExonHit's development", added Laurent Condomine, President of the Company's Supervisory Board.

After having held a variety of project management positions in consultancy firms in France and the United States between 1981 and 1989, Hervé Duchesne de Lamotte took up a senior position at a Paris-based asset management firm. In 1998, he moved into pharma and biotechnology by joining the IDM group, where he served as CFO for 10 years in France, Canada, and the United States. He was subsequently appointed Chief Operating Officer, France, at IDM Paris from 2006 to 2008. Prior to joining ExonHit Therapeutics, Hervé Duchesne de Lamotte managed Cirrus Finance Management, a consultancy firm specializing in business and organizational strategies. Hervé Duchesne de Lamotte has an MBA in finance and a Master of Science from MIT. His first degree was in aeronautical engineering.

Hervé Duchesne de Lamotte is joining ExonHit Therapeutics at a time when the company just announced:

- the successful completion of Phase IIa clinical trials for EHT 0202 (its lead drug candidate in Alzheimer's disease) and ongoing discussions with potential partners for further development and commercialization of the drug
- the strengthening of its intellectual property position in the United States
- the launch of AclarusDx™ (formerly EHT Dx21) by the end of 2009
- involvement in the multi-partner Multi-domain Alzheimer Preventive Trial (MAPT) for the identification of early blood biomarkers of Alzheimer's disease.

About ExonHit Therapeutics

ExonHit Therapeutics (Alternext: ALEHT) is a fast-emerging healthcare player active in both therapeutics and diagnostics. The company is applying its proprietary technology (based on the analysis of alternative RNA splicing) to develop innovative molecular diagnostic tests and therapeutics for neurodegenerative and cancer indications. ExonHit has a balanced investment strategy with in-house development programs and strategic collaborations (in particular with bioMérieux and Allergan).

ExonHit is headquartered in Paris, France and has U.S. offices in Gaithersburg, Maryland. The company is listed on Alternext of NYSE Euronext Paris. For more information, please visit <http://www.exonhit.com>.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Lastly, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

ExonHit Therapeutics

Media contact

Corinne Hoff
+33 1 58 05 47 04
corinne.hoff@exonhit.com

ALIZE RP

Caroline Carmagnol
+ 33 6 64 18 99 59
caroline@alizerp.com

Investor contact

Loïc Maurel
+33 1 53 94 77 00
loic.maurel@exonhit.com